Phase II Trial of Erlotinib and Concurrent Palliative Thoracic Radiation Therapy for Non-small Cell Lung Cancer (PEARL)

Sponsor
Ontario Clinical Oncology Group (OCOG)
Study ID
NCT00391248
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Erlotinib — DRUG
    150 mg in a single daily dose, starting Day 1 through Day 22

Study Details

To improve the clinical outcomes of patients with non-small cell lung cancer treated with radiation therapy.

Key Dates

First listed
Oct 23, 2006
Start date
Nov 30, 2006
Status verified
Apr 2011
Primary completion
Dec 31, 2012
Completion
Dec 31, 2012

Study Design

Enrollment
40 participants (actual)
Allocation
NON_RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Primary Outcome Measure

The mean improvement of "lung cancer symptoms" as measured by the Lung Cancer Symptom Scale at four weeks following completion of radiation therapy [ Time Frame: 4 weeks post radiotherapy ]

Related Studies